CuraGen, a clinical-stage biopharmaceutical company, has announced encouraging preliminary data from an ongoing Phase II trial of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, a human gene, for the treatment of patients with unresectable stage III or stage IV melanoma.

CuraGen has announced the treatment of the first patient in its CR011-vcMMAE Phase II breast cancer study.

CuraGen has announced that its Phase II trial evaluating CR011-vcMMAE for the treatment of patients with unresectable stage III or stage IV melanoma has met the efficacy criteria for advancement to the second stage of enrollment.

CuraGen has presented encouraging results from the ongoing Phase I/II study of CR011-vcMMAE for the treatment of unresectable Stage III or Stage IV melanoma.

CuraGen and TopoTarget have initiated patient dosing in a Phase II open-label, multi-center clinical trial evaluating the efficacy and safety of intravenous belinostat, a small molecule histone deacetylase inhibitor, for the treatment of patients with previously-treated thymoma and thymic carcinoma.